Cargando…

Meta-analysis of gene expression disease signatures in colonic biopsy tissue from patients with ulcerative colitis

Publicly available ulcerative colitis (UC) gene expression datasets from observational studies and clinical trials include inherently heterogeneous disease characteristics and methodology. We used meta-analysis to identify a robust UC gene signature from inflamed biopsies. Eight gene expression data...

Descripción completa

Detalles Bibliográficos
Autores principales:	Linggi, Bryan, Jairath, Vipul, Zou, Guangyong, Shackelton, Lisa M., McGovern, Dermot P. B., Salas, Azucena, Verstockt, Bram, Silverberg, Mark S., Nayeri, Shadi, Feagan, Brian G., Vande Casteele, Niels
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8440637/ https://www.ncbi.nlm.nih.gov/pubmed/34521888 http://dx.doi.org/10.1038/s41598-021-97366-5

Ejemplares similares

Centrally Determined Standardization of Flow Cytometry Methods Reduces Interlaboratory Variation in a Prospective Multicenter Study
por: Westera, Liset, et al.
Publicado: (2017)

Tofacitinib, two-faced Janus in ulcerative colitis and Crohn’s disease?
por: Biemans, Vince BC, et al.
Publicado: (2020)

Development of the symptoms and impacts questionnaire for Crohn's disease and ulcerative colitis
por: Dulai, Parambir S., et al.
Publicado: (2020)

Reliability of the Endoscopic Ultrasound Ulcerative Colitis (EUS-UC) score for assessment of inflammation in patients with ulcerative colitis
por: Yan, Brian M., et al.
Publicado: (2021)

Molecular Changes in the Non-Inflamed Terminal Ileum of Patients with Ulcerative Colitis
por: Lee, Ho-Su, et al.
Publicado: (2020)

Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn’s disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial)
por: Papamichael, Konstantinos, et al.
Publicado: (2022)

Ozanimod Therapy in a Patient With Ulcerative Colitis and Multiple Sclerosis: Hitting 2 Birds With 1 Stone
por: Vuyyuru, Sudheer K., et al.
Publicado: (2023)

A156 MUCOSA-ASSOCIATED MICROBIOTA OF ILEOCOLONIC CROHN’S DISEASE PATIENTS IS DISTINCT FROM COLONIC CROHN’S DISEASE AND ULCERATIVE COLITIS PATIENTS INDEPENDENT OF BIOPSY SITE, ENDOSCOPIC INFLAMMATION AND HOST GENETICS
por: Hernandez-Rocha, C, et al.
Publicado: (2022)

Changes in health-related quality of life and associations with improvements in clinical efficacy: a Phase 2 study of mirikizumab in patients with ulcerative colitis
por: Dubinsky, Marla C, et al.
Publicado: (2023)

A comparison of approaches for adjudicating outcomes in clinical trials
por: Kahan, Brennan C., et al.
Publicado: (2017)

Mirikizumab Improves Quality of Life in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Induction and LUCENT-2 Maintenance Studies
por: Sands, Bruce E, et al.
Publicado: (2023)

Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis
por: Dulai, Parambir S., et al.
Publicado: (2020)

Definition of mild to moderate ulcerative colitis in clinical trials: A systematic literature review
por: Caron, Bénédicte, et al.
Publicado: (2022)

Evaluating cost per remission and cost of serious adverse events of advanced therapies for ulcerative colitis
por: Jairath, Vipul, et al.
Publicado: (2022)

Recommendations for standardizing biopsy acquisition and histological assessment of immune checkpoint inhibitor-associated colitis
por: Ma, Christopher, et al.
Publicado: (2022)

Comparative efficacy of advanced treatments in biologic-naïve or biologic-experienced patients with ulcerative colitis: a systematic review and network meta-analysis
por: Lu, Xiaoyan, et al.
Publicado: (2022)

Correction to: Comparative efficacy of advanced treatments in biologic-naïve or biologic-experienced patients with ulcerative colitis: a systematic review and network meta-analysis
por: Lu, Xiaoyan, et al.
Publicado: (2023)

Resolving Histological Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programmes
por: Magro, Fernando, et al.
Publicado: (2023)

Managing Inflammatory Bowel Disease During COVID-19: Summary of Recommendations from Gastrointestinal Societies
por: Hanzel, Jurij, et al.
Publicado: (2020)

Expression Levels of 4 Genes in Colon Tissue Might Be Used to Predict Which Patients Will Enter Endoscopic Remission After Vedolizumab Therapy for Inflammatory Bowel Diseases
por: Verstockt, Bram, et al.
Publicado: (2020)

A235 ILEAL MICROBIOME ALPHA DIVERSITY REMAINS LOWER IN ENDOSCOPICALLY AND HISTOLOGICALLY INACTIVE CROHN’S DISEASE COMPARED TO ULCERATIVE COLITIS OR HEALTHY CONTROLS
por: Olivera Sendra, P A, et al.
Publicado: (2022)

International Consensus on Definition of Mild-to-Moderate Ulcerative Colitis Disease Activity in Adult Patients
por: Caron, Bénédicte, et al.
Publicado: (2023)

p53 mutation in patients with ulcerative colitis in rectal biopsy
por: Kim, Hyung-Joon, et al.
Publicado: (1998)

Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)
por: Travis, Simon P L, et al.
Publicado: (2011)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Exposure‐response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease
por: Vande Casteele, N., et al.
Publicado: (2017)

Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Crohn Disease: A Theoretical Construct to Apply Pharmacokinetics and Guidelines to Clinical Practice
por: Vande Casteele, Niels, et al.
Publicado: (2020)

Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease
por: Rosario, M., et al.
Publicado: (2015)

A systems genomics approach to uncover patient-specific pathogenic pathways and proteins in ulcerative colitis
por: Brooks-Warburton, Johanne, et al.
Publicado: (2022)

Clinical Pharmacology of Janus Kinase Inhibitors in Inflammatory Bowel Disease
por: Lefevre, Pavine L C, et al.
Publicado: (2020)

Right dorsal colitis in the horse: minireview and reports on three cases in Ireland
por: Galvin, Noreen, et al.
Publicado: (2004)

Medical Therapy of Active Ulcerative Colitis
por: Bürger, Martin, et al.
Publicado: (2015)

Randomised clinical trial: a phase 1, dose‐ranging study of the anti‐matrix metalloproteinase‐9 monoclonal antibody GS‐5745 versus placebo for ulcerative colitis
por: Sandborn, W. J., et al.
Publicado: (2016)

Neutrophil Extracellular Traps in Ulcerative Colitis: A Proteome Analysis of Intestinal Biopsies
por: Bennike, Tue Bjerg, et al.
Publicado: (2015)

Molecular detection of pathogenic bacteria in the colonic biopsies from patients with Ulcerative Colitis
por: El A Helal, Thanaa, et al.
Publicado: (2022)

Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis
por: Feagan, Brian G, et al.
Publicado: (2019)

Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study
por: Cleynen, Isabelle, et al.
Publicado: (2016)

A Phase 1b Safety Study of SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative Colitis
por: Henn, Matthew R., et al.
Publicado: (2021)

ULCERATIVE COLITIS
Publicado: (1969)

Effects of vedolizumab on health‐related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial
por: Feagan, B. G., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_go7ba3h7kahrf2ah40as5gfp3m